Carpal tunnel syndrome Nervous System Diseases
Conditions
Interventions
The patients were randomly categorized a in 1:1:1 ratio into three groups PRP (i) group, PRP (ii) group and a third group (CS) that received local corticosteroid injection. Randomization was done by a
the plasma was separated from packed red blood cells and re-centrifuged at 3700 rpm for 10 min. The upper two-third volume of plasma, which is poor in platelets, was removed
the platelet pellet was suspended in a minimum quantity of plasma by gently shaking the tube and the PRP was activated endogenously the soft tissue collagen. The remnant PRP was counted using the cell
Sponsors
Zagazig University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosed with very mild to moderate unilateral CTS 2. Aged 18-65 years
Exclusion criteria
Exclusion criteria: 1. Severe CTS 2. Bilateral CTS 3. Received non-steroidal anti-inflammatory drugs (NSAIDs) within 2 weeks of the study start 4. History of wrist surgery, polyneuropathy, cervical spondylosis, brachial plexopathy or thoracic outlet syndrome 5. History of thrombocytopenia or platelet dysfunction 6. Systemic infection 7. Renal or hepatic disease 8. Pregnancy 9. Previous steroid injection or surgical treatments for CTS 10. Psychiatric disorders or serious mental stress 11. Use of corticosteroid or anticlotting drugs 12. Diabetes mellitus 13. Uncontrolled hypothyroidism 14. Rheumatological disorders
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Pain assessed using a 1-10 visual analogue scale (VAS) reported by the patient at at 1.5 and 3 months after injection 2. Symptom severity assessed using the Boston Carpal Tunnel Syndrome Questionnaire (BCTSQ) at time of diagnosis and at 1.5 and 3 months after injection of treatment 3. Functional outcome assessed using the Boston Carpal Tunnel Syndrome Questionnaire (BCTSQ) at time of diagnosis and at 1.5 and 3 months after injection of treatment BCTSQ evaluates two domains of CTS: (i) symptoms severity using a scale of 11 items (pain, paresthesia, numbness, weakness and nocturnal symptoms), and (ii) functional assessment using a scale of eight items (writing, buttoning, holding, gripping, bathing and dressing). The questionnaire is in a multiple choice format with scores ranging from 1 (mildest) to 5 (most severe). Each score was calculated as the mean of the response of the individual items. | — |
Secondary
| Measure | Time frame |
|---|---|
| Electrophysiological grading of CTS assessed using a nerve conduction velocity test at diagnosis and 1.5 and 3 months after injection of treatment The electrophysiological study was conducted as per the American Association of Electrodiagnostic Medicine protocol by an expert neurologist. According to the neurophysiological grading for CTS, patients were classified as follows: very mild (grade 1), CTS confirmed only with most sensitive tests (e.g., inching, combined sensory index, palm/wrist median/ulnar comparison); mild (grade 2), only orthodromic sensory nerve conduction velocity slow at 4.5 ms and <6.5 ms with preserved sensory nerve action potential of the index finger. | — |
Countries
Egypt
Outcome results
None listed